Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Non-Current Liabilities (2016 - 2025)

Vanda Pharmaceuticals' Other Non-Current Liabilities history spans 13 years, with the latest figure at $9.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 0.56% year-over-year to $9.5 million; the TTM value through Dec 2025 reached $9.5 million, down 0.56%, while the annual FY2025 figure was $9.5 million, 0.56% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $9.5 million at Vanda Pharmaceuticals, down from $11.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $11.0 million in Q3 2025 and bottomed at $1.0 million in Q1 2022.
  • The 5-year median for Other Non-Current Liabilities is $6.7 million (2022), against an average of $6.7 million.
  • The largest annual shift saw Other Non-Current Liabilities tumbled 61.09% in 2022 before it soared 540.08% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $4.4 million in 2021, then soared by 54.9% to $6.8 million in 2022, then grew by 29.81% to $8.8 million in 2023, then rose by 8.61% to $9.6 million in 2024, then fell by 0.56% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Other Non-Current Liabilities are $9.5 million (Q4 2025), $11.0 million (Q3 2025), and $10.0 million (Q2 2025).